TSE:GUD Knight Therapeutics (GUD) Stock Price, News & Analysis C$9.31 -0.45 (-4.61%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesBuy This Stock About Knight Therapeutics Stock (TSE:GUD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Knight Therapeutics alerts:Sign Up Key Stats Today's RangeC$9.31▼C$9.8250-Day RangeC$8.20▼C$10.0752-Week RangeC$5.66▼C$10.17Volume68,423 shsAverage Volume98,784 shsMarket CapitalizationC$914.54 millionP/E Ratio155.17Dividend YieldN/APrice TargetC$9.50Consensus RatingBuy Company Overview Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca. Read More Knight Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreGUD MarketRank™: Knight Therapeutics scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingBuy Consensus RatingKnight Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Knight Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageKnight Therapeutics has received no research coverage in the past 90 days.Read more about Knight Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Knight Therapeutics is 155.17, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.13.Price to Earnings Ratio vs. SectorThe P/E ratio of Knight Therapeutics is 155.17, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 269.19.Price to Earnings Growth RatioDue to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.Price to Book Value per Share RatioKnight Therapeutics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GUD. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKnight Therapeutics does not currently pay a dividend.Dividend GrowthKnight Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.36 News SentimentKnight Therapeutics has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Knight Therapeutics this week, compared to 0 articles on an average week. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Knight Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders45.62% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions22.73% of the stock of Knight Therapeutics is held by institutions.Read more about Knight Therapeutics' insider trading history. Receive GUD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GUD Stock News HeadlinesNotice of Knight Therapeutics' Second Quarter 2026 Results Conference CallJuly 30, 2026 | markets.businessinsider.comKnight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.August 10 at 1:00 AM | Porter & Company (Ad)Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2026 | markets.businessinsider.comTSX Value Picks Knight Therapeutics And 2 Other Stocks Estimated Below Intrinsic ValueMarch 25, 2026 | uk.finance.yahoo.comKnight Therapeutics advances chronic GvHD expansion strategyFebruary 27, 2026 | finance.yahoo.com3 TSX Growth Companies With Insider Ownership As High As 27%January 28, 2026 | finance.yahoo.comProfound Medical Regains Exclusive Distribution Rights for TULSA-PRO(R) in Canada from KnightNovember 12, 2025 | barrons.comSee More Headlines GUD Stock Analysis - Frequently Asked Questions How have GUD shares performed this year? Knight Therapeutics' stock was trading at C$6.05 at the start of the year. Since then, GUD shares have increased by 53.9% and is now trading at C$9.31. How were Knight Therapeutics' earnings last quarter? Knight Therapeutics Inc. (TSE:GUD) posted its quarterly earnings data on Thursday, August, 6th. The company reported ($0.03) earnings per share for the quarter. The firm had revenue of $143.97 million for the quarter. Knight Therapeutics had a net margin of 2.72% and a trailing twelve-month return on equity of 1.91%. Read the conference call transcript. How do I buy shares of Knight Therapeutics? Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Knight Therapeutics investors own include ARC Resources (ARX), Cenovus Energy (CVE), Enbridge (ENB), Whitecap Resources (WCP), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG) and Suncor Energy (SU). Company Calendar Last Earnings8/06/2026Today8/10/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolTSE:GUD CIKN/A Webwww.gud-knight.com Phone514-484-4483FaxN/AEmployees725Year FoundedN/APrice Target and Rating Average Price Target for Knight TherapeuticsC$9.50 High Price TargetC$9.50 Low Price TargetC$9.50 Potential Upside/Downside+2.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)C$0.06 Trailing P/E Ratio155.17 Forward P/E Ratio92.23 P/E Growth-1013.5Net Income-C$30.73 million Net Margins2.72% Pretax MarginN/A Return on Equity1.91% Return on Assets0.51% Debt Debt-to-Equity Ratio4.29 Current Ratio2.28 Quick Ratio1.79 Sales & Book Value Annual SalesC$510.45 million Price / Sales1.79 Cash FlowC$2.42 per share Price / Cash Flow3.85 Book ValueC$8.13 per share Price / Book1.14Miscellaneous Outstanding Shares98,232,000Free FloatN/AMarket CapC$914.54 million OptionableNot Optionable Beta-0.19 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (TSE:GUD) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored$8B is moving in... are you?Venture capital investment in US crypto companies hit $7.9 billion last year, up 44 percent from the year befo...Awesomely | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe trading strategy that works BECAUSE you have a lifeTim Sykes built a trading strategy for people who can't watch charts from 9:30 to 4:00 every day. It's not ...Tim Sykes | SponsoredReal reason Trump banning Chinese modelsPresident Trump's administration is drafting a ban on Chinese-made components used inside American AI data cen...Porter & Company | SponsoredA $5 stock inside Kennedy Space Center?A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...Freedom Financial | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredEric Fry’s super simple investing mantraFormer Wall Street money manager Eric Fry says buy and hold investing is outdated. Instead, he built his caree...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
